Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 versus docetaxel or irinotecan in second-line advanced gastric cancer
2009-015407-47Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Luminespib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Novartis. Primary endpoint: Primary objective. Started Feb 2010; status: terminated.
02
Drugs
Luminespib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-015407-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015407-47.